Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Company Overview - Immunovant, Inc. (NASDAQ: IMVT) is planning to initiate a pivotal registration study for its lead candidate IMVT-1402, targeting the treatment of Graves' Disease before the end of 2024 [2]. Product Development - IMVT-1402 is an FcRn inhibitor designed to block the receptor involved in the pathophysiology of Graves' Disease, indicating a focused approach to addressing this specific condition [2].